We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva and MedinCell Receive Complete Response Letter for Schizophrenia Drug
Teva and MedinCell Receive Complete Response Letter for Schizophrenia Drug
The FDA has sent both Teva Pharmaceuticals and France-based MedinCell a Complete Response Letter regarding their joint new drug application (NDA) for TV-46000/mdc-IRM, their extended-release formulation of risperidone for the treatment of patients with schizophrenia.